MX2015009940A - Biomarcadores de diabetes tipo 2 y sus usos. - Google Patents

Biomarcadores de diabetes tipo 2 y sus usos.

Info

Publication number
MX2015009940A
MX2015009940A MX2015009940A MX2015009940A MX2015009940A MX 2015009940 A MX2015009940 A MX 2015009940A MX 2015009940 A MX2015009940 A MX 2015009940A MX 2015009940 A MX2015009940 A MX 2015009940A MX 2015009940 A MX2015009940 A MX 2015009940A
Authority
MX
Mexico
Prior art keywords
glucose tolerance
diabetes
development
subject
type
Prior art date
Application number
MX2015009940A
Other languages
English (en)
Inventor
Eustache Paramithiotis
Pascal Croteau
Joel Lanoix
Erik Joly
S R Murthy Madiraju
Marc Prentki
Rèmi Rabasa-Lhoret
Original Assignee
Caprion Proteomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Caprion Proteomics Inc filed Critical Caprion Proteomics Inc
Publication of MX2015009940A publication Critical patent/MX2015009940A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención proporciona los biomarcadores, los métodos y kits para el diagnóstico y pronóstico del desarrollo de intolerancia a la glucosa en un individuo y la progresión de la diabetes en un individuo, así como los métodos para identificar un compuesto que pueda inhibir el desarrollo de intolerancia a la glucosa y/o diabetes tipo 2; reducir o ralentizar la progresión de tolerancia normal a la glucosa a alteración de la glicemia en ayuno, a intolerancia a la glucosa y/o a diabetes; y/o que reduzca o inhiba el desarrollo de complicaciones asociadas con la enfermedad en un individuo, y métodos para inhibir el desarrollo de intolerancia a la glucosa y/o diabetes tipo 2; para reducir o ralentizar la progresión de la tolerancia normal a la glucosa a alteración de la glicemia en ayuno, a intolerancia a la glucosa y/o a diabetes; y/o para reducir o inhibir el desarrollo de complicaciones asociadas con la enfermedad en un individuo.
MX2015009940A 2013-01-31 2014-01-31 Biomarcadores de diabetes tipo 2 y sus usos. MX2015009940A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361758987P 2013-01-31 2013-01-31
PCT/IB2014/000426 WO2014118634A1 (en) 2013-01-31 2014-01-31 Type 2 diabetes biomarkers and uses thereof

Publications (1)

Publication Number Publication Date
MX2015009940A true MX2015009940A (es) 2016-03-11

Family

ID=51261524

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015009940A MX2015009940A (es) 2013-01-31 2014-01-31 Biomarcadores de diabetes tipo 2 y sus usos.

Country Status (12)

Country Link
US (1) US10338081B2 (es)
EP (1) EP2951575A4 (es)
JP (1) JP2016510409A (es)
CN (1) CN105393117A (es)
AU (1) AU2014210871A1 (es)
BR (1) BR112015018463A2 (es)
CA (1) CA2900024A1 (es)
HK (1) HK1218329A1 (es)
IL (1) IL240285A0 (es)
MX (1) MX2015009940A (es)
RU (1) RU2015136673A (es)
WO (1) WO2014118634A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201415369D0 (en) * 2014-08-29 2014-10-15 Iles Raymond K Rapid screening and evaluation of diabetes and prediabetes by glycated haemoglobin mass spectrometry
EP3115784A1 (en) * 2015-07-10 2017-01-11 Koss, Michael Janusz Polypeptide marker for analysis, diagnosis and therapy of eye-related diseases
US10294297B2 (en) 2016-01-29 2019-05-21 The Board Of Trustees Of The Leland Stanford Junior University Methods for treatment using anti-NMU agents
WO2017194499A1 (en) * 2016-05-09 2017-11-16 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Tissue-specific exosomes as biomarkers
CN106093430A (zh) * 2016-06-06 2016-11-09 上海阿趣生物科技有限公司 可用于检测糖尿病的标志物及其用途
DK3552022T3 (da) * 2016-11-25 2021-08-23 Implexion AB Metaboliske lidelser
RU2655635C1 (ru) * 2017-03-16 2018-05-29 Федеральное государственное автономное образовательное учреждение высшего образования "Балтийский федеральный университет имени Иммануила Канта" (БФУ им. И. Канта) Способ ранней генетической диагностики риска развития сахарного диабета 2 типа
NZ763766A (en) 2017-03-20 2023-07-28 Novo Nordisk Healthcare Ag Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators
EP3714273A1 (en) 2017-11-20 2020-09-30 Zora Biosciences OY Methods for prediction and early detection of diabetes
CN110527717B (zh) * 2018-01-31 2023-08-18 完美（广东）日用品有限公司 用于2型糖尿病的生物标志物及其用途
CN108572256B (zh) * 2018-04-24 2021-03-16 上海市第十人民医院 肝癌血清标志物cpe
EP3852791B1 (en) 2018-09-19 2024-07-03 Novo Nordisk Health Care AG Activating pyruvate kinase r
BR112021005188A2 (pt) 2018-09-19 2021-06-08 Forma Therapeutics, Inc. tratamento de anemia falciforme com um composto de ativação de piruvato cinase r
CN111458511A (zh) * 2019-01-21 2020-07-28 中国科学院分子细胞科学卓越创新中心 一种动脉粥样硬化生物标志物及其用途
CN111458513A (zh) * 2019-01-21 2020-07-28 中国科学院分子细胞科学卓越创新中心 一种动脉粥样硬化生物标志物及其用途
CN111458512A (zh) * 2019-01-21 2020-07-28 中国科学院分子细胞科学卓越创新中心 一种动脉粥样硬化生物标志物及其用途
CN111781356A (zh) * 2019-04-04 2020-10-16 清华大学 一种胃癌极早期细胞标志和胃癌前病变早期细胞标志及其在诊断试剂盒中的应用
RU2739118C1 (ru) * 2019-12-23 2020-12-21 федеральное государственное бюджетное образовательное учреждение высшего образования "Башкирский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ прогнозирования течения острого периода ишемического инсульта у больных сахарным диабетом 2 типа
CN115023615A (zh) * 2020-01-10 2022-09-06 私募蛋白质体操作有限公司 确定葡萄糖耐量减低的方法
KR102301307B1 (ko) * 2020-01-22 2021-09-13 계명대학교 산학협력단 당뇨 조기진단 또는 당뇨병 진단을 위한 바이오마커 및 이의 용도
KR20220146538A (ko) 2020-02-26 2022-11-01 페아엠 테라그노스틱스 게엠베하 치료 목적을 위한 펩티딜글리신 알파-아미드화 모노옥시게나제 (pam)의 용도
CN115280148A (zh) 2020-02-26 2022-11-01 Pam治疗诊断有限公司 测定肽酰甘氨酸α-酰胺化单加氧酶(PAM)的方法及其用于诊断目的的用途
CN112461986B (zh) * 2021-02-03 2021-06-08 首都医科大学附属北京友谊医院 一种用于评估空腹血糖受损和2型糖尿病患病风险的整合生物标志物体系
CN113533730B (zh) * 2021-07-23 2022-09-06 南方医科大学深圳医院 一种血浆外泌体标志物组合及其应用
CN114354827A (zh) * 2022-03-21 2022-04-15 天津云检医疗器械有限公司 代谢标志物及其在制备2型糖尿病的风险预测试剂盒中的应用和试剂盒
WO2024194276A1 (en) 2023-03-17 2024-09-26 Pam Theragnostics Gmbh Methods for determining peptidylglycine alpha-amidating monooxygenase (pam) and its use for diagnostic purpose

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6835545B2 (en) * 2000-05-08 2004-12-28 President And Fellows Of Harvard College Methods, products and treatments for diabetes
WO2007027630A2 (en) * 2005-08-30 2007-03-08 Smithkline Beecham Corporation Genes associated with type ii diabetes mellitus
BRPI0617332A2 (pt) * 2005-10-11 2011-07-26 Tethys Bioscience Inc marcadores asoociados ao diabetes e mÉtodos de uso dos mesmos
WO2008131224A2 (en) * 2007-04-18 2008-10-30 Tethys Bioscience, Inc. Diabetes-related biomarkers and methods of use thereof
US8187830B2 (en) * 2007-07-17 2012-05-29 Metabolon, Inc. Method for determining insulin sensitivity with biomarkers
CN102539779A (zh) * 2010-12-27 2012-07-04 中国科学院上海生命科学研究院 维生素d结合蛋白作为糖尿病标志物的应用

Also Published As

Publication number Publication date
US20150330997A1 (en) 2015-11-19
CN105393117A (zh) 2016-03-09
IL240285A0 (en) 2015-09-24
CA2900024A1 (en) 2014-08-07
RU2015136673A (ru) 2017-03-10
BR112015018463A2 (pt) 2017-08-22
AU2014210871A1 (en) 2015-08-13
EP2951575A4 (en) 2016-11-02
HK1218329A1 (zh) 2017-02-10
US10338081B2 (en) 2019-07-02
JP2016510409A (ja) 2016-04-07
EP2951575A1 (en) 2015-12-09
WO2014118634A1 (en) 2014-08-07

Similar Documents

Publication Publication Date Title
MX2015009940A (es) Biomarcadores de diabetes tipo 2 y sus usos.
WO2014133855A8 (en) Tuberculosis biomarkers and uses thereof
WO2015061634A3 (en) Biomarkers and diagnostic methods for alzheimer's disease and other neurodegenerative disorders
EA033286B1 (ru) Способ лечения или отсрочки развития хронической болезни почек
WO2014160499A3 (en) Methods and compositions for detecting pancreatic cancer
EA201390149A1 (ru) Способы выявления заболевания или патологических состояний с использованием фагоцитарных клеток
BR112015029318A2 (pt) marcadores específicos de caminhos para diagnóstico da síndrome do intestino irritável
BR112015027327A2 (pt) composições e métodos para alterar a sinalização do mensageiro secundário
MX365061B (es) Biomarcadores relacionados a la funcion renal y metodos para usar los mismos.
MX340453B (es) Biomarcadores para cancer de pulmon.
EA201590027A1 (ru) Способы детекции заболеваний или состояний
PH12015502275A1 (en) Therapuetic uses of empagliflozin
BR112013004673A8 (pt) biomarcadores e métodos de tratamento.
EA201400119A1 (ru) Фармацевтическая композиция, способы лечения и их применение
EA201390613A1 (ru) Обогащенный дейтерием расагилин
GT201200293A (es) Marcadores predictivos útiles en el tratamiento del síndrome frágil x (fxs)
EA201500080A1 (ru) Способ in vitro диагностирования и мониторинга рака
MX2015010174A (es) Herramientas de diagnostico para predecir la presentacion de preeclampsia.
TR201911039T4 (tr) Ptp1b ile ilişkili bir hastalığın tedavisine yönelik aminosteroidler.
BR112014009223A8 (pt) método para o diagnóstico da doença de niemann-pick
WO2014187884A3 (en) Mirnas as non-invasive biomarkers for heart failure
MX2016001719A (es) Metodos y equipos para predecir el riesgo de tener una enfermedad o evento cardiovascular.
NZ712023A (en) Caix stratification based cancer treatment
MX2016002529A (es) Marcadores de riesgo para cardiovasculopatias en pacientes con nefropatia cronica.
AU2012371260A8 (en) Predicitive biomarker for cancer treatment with ADCC enhanced antibodies